Jan Rasmussen

Jan Rasmussen

Auto-generated profile, based on publicly available information

Jan Rasmussen

Museum Mors and Natural History Museum of Denmark, Copenhagen

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2013 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JRJan Rasmussen
Jan Rasmussen
ONOlav W. Nielsen
Olav W. Nielsen
NJNils Janzen
Nils Janzen
MDMorten Duno
Morten Duno
HGHannes Gislason
Hannes Gislason
ALAllan M Lund
Allan M Lund

8 May 2012 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JRJan Rasmussen
Jan Rasmussen
ONOlav W. Nielsen
Olav W. Nielsen
ALAllan M Lund
Allan M Lund
LKLars Køber
Lars Køber
HDHøgni Djurhuus
Høgni Djurhuus

21 August 2013 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JRJan Rasmussen
Jan Rasmussen
LKLars Køber
Lars Køber
ALAllan M Lund
Allan M Lund
ONOlav W. Nielsen
Olav W. Nielsen

1 August 2019 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JRJan Rasmussen
Jan Rasmussen
MDMorten Dunø
Morten Dunø
ALAllan M Lund
Allan M Lund
USUlrike Steuerwald
Ulrike Steuerwald
SHSteen‐Holger Hansen
Steen‐Holger Hansen
ONOlav W. Nielsen
Olav W. Nielsen

1 January 2014
Verified
Book Chapter
Closed access
PDF file
JRJ. Rasmussen
J. Rasmussen
JTJ. A. Thomsen
J. A. Thomsen
JOJ. H. Olesen
J. H. Olesen
TLTrine Meldgaard Lund
Trine Meldgaard Lund
MMM. Mohr
M. Mohr
ALAllan M Lund
Allan M Lund

1 January 2014
Verified
Book Chapter
Open access
PDF file
JTJákup Andreas Thomsen
Jákup Andreas Thomsen
ALAllan M Lund
Allan M Lund
JOJess Have Olesen
Jess Have Olesen
MMMagni Mohr
Magni Mohr
JRJan Rasmussen
Jan Rasmussen
Background: 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCd) is an autosomal recessive disorder in the catabolism of leucine. In the present study, we investigated the current and prior medical condition of patients with 3-MCCd in the Faroe Islands and their carnitine levels in blood, urine and muscle tissue with and without l-carnitine supplementation to evaluate the current treatment strategy of not recommending l-carnitine supplementation to Faroese 3-MCCd patients. Methods: Blood and urine samples and muscle biopsies were collected from patients at inclusion and at 3 months. Eight patients received l-carnitine supplementation when recruited; five did not. Included patients who received supplementation were asked to stop l-carnitine, the others were asked to initiate l-carnitine supplementation during the study. Symptoms were determined by review of hospital medical records and questionnaires answered at baseline and after the intervention. Results: The prevalence of 3-MCCd in the Faroe Islands was 1:2,400, the highest reported worldwide. All patients were homozygous for the MCCC1 mutation c.1526delG. When not administered l-carnitine, the 3-MCCd patients (n = 13) had low plasma and muscle free carnitine levels, 6.9 (SD 1.4) μmol/L and 785 (SD 301) nmol/g wet weight, respectively. l-Carnitine supplementation increased muscle and plasma carnitine levels to a low-normal range, 25.5 (SD 10.9) μmol/L and 1,827 (SD 523) nmol/g wet weight, p < 0.01, respectively. Seven of the thirteen 3-MCCd subjects suffered from self-reported fatigue with some alleviation after l-carnitine supplementation. Conclusion: 3-MCCd is common in the Faroe Islands. Some symptomatic 3-MCCd patients may benefit biochemically and clinically from l-carnitine supplementation, a more general recommendation cannot be given.